Latest Breaking News On - Salarius pharmaceuticals - Page 15 : comparemela.com

VolitionRx Limited inks R&D collaboration deals with Xenetic Biosciences Inc and Salarius Pharmaceuticals Inc in push to develop cancer treatments

VolitionRx Limited inks R&D collaboration deals with Xenetic Biosciences Inc and Salarius Pharmaceuticals Inc in push to develop cancer treatments
proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.

City ofUnited kingdomDavid arthurXenetic dnaseSalarius pharmaceuticalsXenetic biosciencesNeutrophil extracellular trapsJake micallef

Salarius Pharmaceuticals to Host Second Quarter 2022 Financial Results and Business Update Conference Call on Monday, August 8, 2022

Salarius Pharmaceuticals to Host Second Quarter 2022 Financial Results and Business Update Conference Call on Monday, August 8, 2022
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesRelationskim sutton golodetzNational pediatric cancer foundationDrug administrationMd anderson cancer centerSalarius pharmaceuticalssalarius pharmaceuticals incExchange commissionSalarius pharmaceuticals incProduct development awardResearch institute of texasCall informationInvestors eventsCanada toll freeSalarius pharmaceuticalssalarius pharmaceuticalsCancer preventionResearch institute

Zacks: Analysts Anticipate Salarius Pharmaceuticals, Inc (NASDAQ:SLRX) to Announce -$0 11 EPS

Analysts expect that Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX – Get Rating) will post earnings per share (EPS) of ($0.11) for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Salarius Pharmaceuticals’ earnings. Salarius Pharmaceuticals posted earnings per share of ($0.07) during the same quarter last year, which would indicate a negative year-over-year […]

Salarius pharmaceuticalsHightower advisorsZacks investment researchRenaissance technologiesSalarius pharmaceuticals incCitadel advisorsMillennium managementSalarius pharmaceuticals get ratingGet ratingSalarius pharmaceuticalInvestment researchTower advisorsSigma advisersNasdaq slrx

Salarius Pharmaceuticals, Inc (NASDAQ:SLRX) Short Interest Update

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX – Get Rating) saw a significant drop in short interest during the month of May. As of May 15th, there was short interest totalling 441,800 shares, a drop of 26.6% from the April 30th total of 602,200 shares. Based on an average trading volume of 1,090,000 shares, the days-to-cover ratio is […]

Salarius pharmaceuticalsHightower advisorsZacks investment researchRenaissance technologiesSalarius pharmaceuticals company profile get ratingSalarius pharmaceuticals incCitadel advisorsMillennium managementGet ratingTower advisorsTwo sigma advisersInvestment researchPharmaceuticals company profileNasdaq slrx

BioSpace Movers & Shakers: Jeffrey Leiden, Don Hayden, Zentalis, Entera and More

Life sciences organizations and companies strengthen their leadership teams and boards with these Movers & Shakers.

United statesAnthony sunJames fosterGlympse bioEli lillyMargaret gilmourVirax biolabsSanjay zaveriTauhid aliJonathan wildeSusan howell jonesJohan baeckKimberly blackwellYair erezJosephf odonnellLefei sun